Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer

Abstract

The combination of capecitabine and erlotinib is active in patients with gemcitabine-refractory pancreatic cancer. This regimen may represent an acceptable treatment option in patients who experience treatment failure with standard first-line therapy with gemcitabine or for whom gemcitabine may not be an appropriate first-line treatment option.